Skip to main content

Joan Genescà Ferrer

Internal medicine doctor expert in hepatology. Special dedication to advanced liver disease, liver cirrhosis and portal hypertension. Interest in non-invasive methods for the diagnosis and control of liver disease, especially liver elastography. Both clinical and experimental research in animal models of liver disease, including therapeutic studies with nanomedicine.

Institutions of which they are part

Head of group
Liver Diseases
Vall Hebron Institut de Recerca
Hepatologia
General Hospital

Joan Genescà Ferrer

Institutions of which they are part

Head of group
Liver Diseases
Vall Hebron Institut de Recerca
Hepatologia
General Hospital

Internal medicine doctor expert in hepatology. Special dedication to advanced liver disease, liver cirrhosis and portal hypertension. Interest in non-invasive methods for the diagnosis and control of liver disease, especially liver elastography. Both clinical and experimental research in animal models of liver disease, including therapeutic studies with nanomedicine.

Chief Liver Unit.
Clinical director of Digestive Diseases.
Professor of Medicine of the UAB.

Projects

Nous tractaments combinats en diferents fases de la cirrosi hepàtica amb hjpertensió portal

IP: Joan Genescà Ferrer
Collaborators: -
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 18146.88
Reference: FI-DGR-2013-14
Duration: 01/02/2013 - 31/01/2016

Nuevos tratamientos combinados en distintas fases de la cirrosis hepática con hipertensión portal

IP: Joan Genescà Ferrer
Collaborators: Immaculada Raurell Saborit
Funding agency: Instituto de Salud Carlos III
Funding: 85305
Reference: PI12/01759
Duration: 01/01/2013 - 30/06/2016

Estabulari

IP: Joan Genescà Ferrer
Collaborators: Immaculada Raurell Saborit
Funding agency: Instituto de Salud Carlos III
Funding: 99000
Reference: CA10/01489
Duration: 01/01/2011 - 22/04/2014

Papel del sistema nervioso simpático en la génesis y mantenimiento de las alteraciones hemodinámicas (vasodilatación mesentérica) de la hipertensión portal (SIMPATHAL)

IP: Joan Genescà Ferrer
Collaborators: Immaculada Raurell Saborit, Maria Nieves Martell Pérez-Alcalde
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 84700
Reference: SAF2009-08354
Duration: 01/01/2010 - 31/12/2012

Ministerio de Ciencia

Related news

Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.

The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.

The research team used nanotechnology to deliver the drug directly to liver cells, which eliminated side effects without reducing effectiveness.

Related professionals

Dunia Muñoz Valdivielso

Dunia Muñoz Valdivielso

Administration and Management
Clinical Neuroimmunology
Read more
Carles Lorenzo Bosquet

Carles Lorenzo Bosquet

Molecular Medical Imaging
Read more
Cristina Berastegui Garcia

Cristina Berastegui Garcia

Main researcher
Pneumology
Read more
Nuria Vidal Tarrasón

Nuria Vidal Tarrasón

Predoctoral researcher
Reconstructive Surgery of the Locomotor System
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.